



March 12, 2008

Dear CMS Customers and Partners:

We are pleased to report that the previously announced acquisition of CMS, Inc. by Elekta AB has been successfully completed. CMS's resources and expertise in the area of radiation treatment planning will help strengthen and accelerate Elekta's long-term strategy and vision, and working together we have the opportunity to fundamentally transform clinical practice in a manner that delivers significant benefits to our customers and their patients. CMS brings world-class RTP sales, marketing, product development and support capabilities to the Elekta organization as well as a leading edge product portfolio and product roadmap that complement and enhance Elekta's offerings for the global radiotherapy marketplace.

CMS will form the basis of the treatment planning arm of Elekta and will work closely with our colleagues at IMPAC, also an Elekta company, to accelerate the development of a next-generation EMR-centric distributed adaptive radiotherapy software solution that integrates the complementary capabilities of our respective product portfolios. CMS will also continue to develop, sell and support its products on a stand-alone basis, and will continue to collaborate with all equipment providers in order to support emerging treatment technologies including VMAT for Elekta linacs with single arc or multiple arc treatments, as well as VMAT for Varian linacs using single arc.

Additionally, we would like to take this opportunity to reaffirm and reinforce to our customers, collaborators and strategic partners CMS's and Elekta's ongoing commitment to open platforms and vendor independent solutions. Consistent with Elekta's and IMPAC's approach to the marketplace, CMS will maintain its support for multiple vendors, including Varian and Siemens, and continue to promote freedom, flexibility and choice in any clinical environment.

Together, our combined organizations have over 2,500 employees around the world focused on delivering solutions for advanced and efficient patient care and, our products are used to plan, treat and manage the care over 100,000 patients each day at over 5,000 facilities worldwide. We are excited about the opportunities that lie ahead for CMS as part of the Elekta family, and the opportunities we have to advance clinical practice for the benefit of our customers and their patients.

Best regards,

A handwritten signature in black ink, appearing to read "Andrew C. Cowen".

Andrew C. Cowen  
President and CEO  
CMS, Inc.

A handwritten signature in black ink, appearing to read "Tomas Puusepp".

Tomas Puusepp  
President and CEO  
Elekta AB